Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062987 | 0.91 | AVPR1B (0.49) | AVPR1BUSP2TSHRALDH1A1TP53 | |
| SCHEMBL4056005 | 0.85 | HPGD (0.52) | GRIN1GRIN2BUSP2KDM4EALDH1A1 | |
| SCHEMBL4061236 | 0.85 | ADORA2B (0.45) | GRIN1GRIN2BHRH3AVPR1BKDM4E | |
| SCHEMBL4061731 | 0.84 | TP53 (0.45) | AVPR1BTSHRKDM4EALDH1A1TP53 | |
| SCHEMBL4061314 | 0.84 | NR1H2 (0.46) | GRIN1GRIN2BUSP2TSHRKDM4E | |
| SCHEMBL4052208 | 0.83 | GRIK2 (0.48) | GRIN1GRIN2BKDM4EALDH1A1KMT2A | |
| SCHEMBL4054527 | 0.82 | TP53 (0.48) | TSHRKDM4EALDH1A1TP53MAPT | |
| SCHEMBL4055524 | 0.81 | KDM4E (0.42) | GRIN1GRIN2BTSHRKDM4EALDH1A1 | |
| SCHEMBL4060480 | 0.81 | GRIN1 (0.48) | GRIN1GRIN2BHRH3KDM4EALDH1A1 | |
| SCHEMBL4049864 | 0.81 | BRD4 (0.51) | GRIN1GRIN2BUSP2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | BACE1 1937/4885LTA4H 3552/4885GRIN1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.